NOVNz Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 91.02 |
| 52 Week High | CHF 102.72 |
| 52 Week Low | CHF 83.62 |
| Beta | 0.51 |
| 11 Month Change | -9.97% |
| 3 Month Change | -9.16% |
| 1 Year Change | 6.91% |
| 33 Year Change | 17.99% |
| 5 Year Change | n/a |
| Change since IPO | 83.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVNz | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -1.5% | -1.1% | 1.0% |
| 1Y | 6.9% | -3.2% | 6.3% |
Return vs Industry: NOVNz exceeded the UK Pharmaceuticals industry which returned -3.2% over the past year.
Return vs Market: NOVNz matched the UK Market which returned 6.1% over the past year.
Price Volatility
| NOVNz volatility | |
|---|---|
| NOVNz Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NOVNz has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: NOVNz's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Novartis AG Fundamentals Summary
| NOVNz fundamental statistics | |
|---|---|
| Market cap | CHF 182.05b |
| Earnings (TTM) | CHF 10.38b |
| Revenue (TTM) | CHF 44.07b |
17.5x
P/E Ratio4.1x
P/S RatioIs NOVNz overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVNz income statement (TTM) | |
|---|---|
| Revenue | US$49.94b |
| Cost of Revenue | US$12.07b |
| Gross Profit | US$37.87b |
| Other Expenses | US$26.11b |
| Earnings | US$11.76b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 5.88 |
| Gross Margin | 75.83% |
| Net Profit Margin | 23.55% |
| Debt/Equity Ratio | 69.8% |
How did NOVNz perform over the long term?
See historical performance and comparison